The Drug Industry Might Have Dodged A Build Back Better Bullet But Remains In Congressional Crosshairs Industry critics have managed to get a foothold with reforms that will have devastating, long-term effects for patients and drug companies alike. And worse, they were included in a bill that could actually pass via the special reconciliation process that governs federal budgeting.